I am a hematologist who specializes in treating patients with blood cancers, specifically leukemia and myelodysplastic syndromes. I received my Master of Science in Clinical Oncology and my medical degree from the Ain Shams University Faculty of Medicine, then went on to complete my fellowship of hematology and oncology at West Virginia University.
My primary research interest is investigating the clinical application of immune-based therapies for hematological diseases. I have investigated the role of ?d+ T cell-based therapy after allogeneic stem cell transplantation to enhance immune recovery and decrease relapse risk. I have also investigated the use of attenuated conditioning regimen for allogeneic stem cell transplantation (for acute lymphoblastic leukemia to decrease risk of toxicity) and the use of modified T cell dose in the stem cell graft to decrease the risk of graft versus host disease following the transplant procedure. I am currently investigating (in collaboration with national and European transplant registries) the role of allogeneic stem cell transplantation as a curative therapy for erythropoietic protoporphyria, an uncommon hereditary inborn error of metabolism.
Along with my role as a faculty member in the Department of Internal Medicine, Division of Hematology at The Ohio State University, I am a member of a number of professional societies, including the American College of Physicians and the American Society of Clinical Oncology, and currently serve as the chair of the National Comprehensive Cancer Network (NCCN) committee on stem cell transplantation.
At The James, we utilize the most cutting-edge blood cancer treatments and offer a tremendous variety of clinical trials that are testing novel therapies in the pipeline for cancer care. In addition to the incredible resources at the OSUCCC – James, I enjoy the collegiality and cooperation among my peers and fellow employees, all of whom share a dedication and passion to deliver the best patient care possible.
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Saad has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.